What does it take to develop new antibiotics and ensure they reach the patients who need them most?
In 2025, GARDP reached important milestones in the fight against antimicrobial resistance (AMR),...
What does it take to develop new antibiotics and ensure they reach the patients who need them most?
In 2025, GARDP reached important milestones in the fight against antimicrobial resistance (AMR),...
Peptide Dangers: The Risks Behind This Health Trend #TheIdexPodcast
Health podcasts and influencers praise peptides as health boosts but they lack clinical studies and aren't licensed medicine. Counterfeit drugs are dangerous, you never know what you're injecting.
...
Learn how the European Medicines Agency's PRIME (PRIority MEdicines) scheme helps accelerate the development of promising medicines for patients with unmet medical needs.
In this video, Kevin Cunn...
Learn how the European Medicines Agency's PRIME (PRIority MEdicines) scheme helps accelerate the development of promising medicines for patients with unmet medical needs.
In this video, Kevin Cunn...
...erapies to treat anxiety and depression will soon be available by prescription. Pharmaceutical companies are investing heavily in research and the White House has directed the FDA to ...
Watch all 2026 Global Conference session replays: https://milkeninstitute.org/events/global-conference-2026/program?utm_medium=social&utm_source=youtube&utm_campaign=gc26_post-event-content...
The emerging threat of orphines: New synthetic opioids raising global public health concerns
This presentation was recorded on 4 June 2026 for the Australian Prompt Response Network (PRN) national meeting held on 16 June 2026. It provides a brief overview of the emergence of orphines, incl...
China is the second-largest developer of new medicines, with its companies running an increasing share of the world’s clinical trials. It is also rising to the top in several critical areas of rese...
Corinne de Vries, EMA lead on medicines in pregnancy and breastfeeding, explains how better safety data can be generated at every stage of a medicine’s lifecycle.
Up to 90% of women who are pregnant or breastfeeding use medicines, yet for many of these treatments, reliable safety data remains limited. Why does this gap exist—and how can it be addressed?
In ...
What if the patient, and not just the molecule, actually drives medical progress? The combination of clinical, real‑world, and patient‑reported data across the full care journey — from pre-clinical...
Are you interested in finding out which research needs ECHA added to its Key areas of regulatory challenge report? If so, this webinar is for you. It will cover these topics in detail, followed by ...
...erapies to treat anxiety and depression will soon be available by prescription. Pharmaceutical companies are investing heavily in research and the White House has directed the FDA to ...
...esses once thought incurable, prevent or treat rare diseases long overlooked by pharmaceutical companies, and develop therapies to defeat bacteria that outmaneuver every known antibio...
USP MethodConnect is the first digital library based on USP–NF test methods, designed to deliver verified, execution-ready content directly into the laboratory platforms labs already use, including...
...ts, garments usually come to mind. But there’s another quiet success story: its pharmaceutical industry. Medicines made in Bangladesh are reaching patients in over a hundred countries...
This presentation, delivered by Verily Health Distinguished Engineer David Glazer at Bio-IT World 2026, explores strategies for accelerating biomedical discovery by reducing the "friction" associat...
...itors. Over the past year, the Council on Foreign Relations convened a group of pharmaceutical and biotech specialists, China scholars, and industrial policy experts to address this d...
What does the future of medicines regulation look like in the age of AI and big data?
In this conversation, Prof. Dr. Karl Broich, President of BfArM, and Dr. Peter Arlett, Head of the Data Analyti...